Status:
RECRUITING
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
Lead Sponsor:
Huashan Hospital
Conditions:
COVID-19
Eligibility:
All Genders
12+ years
Brief Summary
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
Detailed Description
The study is a real-world study and the case records of patients with COVID-19 who visit Huashan Hospital affiliated to Fudan University from 2022 to 2027 and receive Paxlovid therapy will be collecte...
Eligibility Criteria
Inclusion
- Participants who have a positive SARS-CoV-2 test result;
- Participants who have one or more mild or moderate COVID-19 symptoms.
Exclusion
- No specific exclusion criteria in this real world study.
Key Trial Info
Start Date :
March 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2027
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT05387369
Start Date
March 21 2022
End Date
March 30 2027
Last Update
May 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital Affiliated to Fudan University
Shanghai, China